Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)-Reference-Cited by-同舟云学术

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

Published:2011-11 Issue:11 Volume:6 Page:1872-1880
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Thongprasert Sumitra,Duffield Emma,Saijo Nagahiro,Wu Yi-Long,Yang James Chih-Hsin,Chu Da-Tong,Liao Meilin,Chen Yuh-Min,Kuo Han-Pin,Negoro Shunichi,Lam Kwok Chi,Armour Alison,Magill Patrick,Fukuoka Masahiro

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Symptoms in adults with lung cancer: a systematic research review;Cooley;J Pain Symptom Manage,2000

2. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer;Natale;Semin Oncol,2004

3. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial;Cella;J Clin Oncol,2005

4. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options;William;Ann Oncol,2009

5. Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors;LoRusso;Clin Cancer Res,2003

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of tumor abnormal protein expression and epidermal growth factor receptor mutation status in non-small cell lung cancer;Discover Oncology;2024-07-09

2. Dynamic immune signatures of patients with advanced non–small-cell lung cancer for infection prediction after immunotherapy;Frontiers in Immunology;2024-01-26

3. Health Outcomes with Curative and Palliative Therapies in Real World: Role of the Quality of Life Summary Score in Thoracic Oncology Patients;Cancers;2023-07-27

4. Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present);Pharmaceuticals;2023-04-03

5. Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions;Respiratory Medicine;2023-01